Society for Translational Oncology navigateright Episode
Ryan Sullivan, MD
Massachusetts General Hospital
While immune checkpoint inhibitors may be associated with remarkable responses that may be complete and durable, most patients will not respond to therapy, and a significant minority of patients who do respond will develop disease progression. The field’s understanding into the underlying mechanisms of resistance to therapy is emerging. The objectives of this presentation are to review the clinical data supporting the use of immune checkpoint inhibitors in melanoma as a test case, review specific cases of intrinsic and acquired resistance, describe the known mechanisms of resistance, and propose potential therapies to overcome therapeutic resistance.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.